ArticleInternational journal of pharmaceutics: X2025
Selective laser sintering of distinct drug and polymer layers as a novel manufacturing strategy for individually dosed tablets.
Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective Laser Sintering (SLS) is an emerging additive manufacturing technology with potential for the production of personalized pharmaceuticals. In this study, we investigated a novel simplified formulation approach in SLS-based manufacturing of individually dosed, multi-layered tablets with distinct layers of pure active pharmaceutical ingredient (API) and excipient. Indomethacin (IND) was chosen as the model API, and polyvinyl alcohol (PVA) served as the excipient. Unlike conventional methods requiring powder blending, this approach utilizes separate powder tanks for IND and PVA, enabling direct printing of alternating layers in a single-step procedure. We successfully fabricated tablets with controlled IND doses by varying the number of IND layers, maintaining consistent printing parameters across different compositions and confirming the API's chemical stability in the product. Since SLS is conventionally used for thermoplastic substances, the successful sintering of pure IND layers was a key achievement in the study, as this crystalline API is typically not printable separately. Energy dispersive X-ray spectroscopy (EDS) demonstrated the successful formation of distinct API and excipient layers. Differential scanning calorimetry (DSC) characterization revealed that the sintering process partially amorphized IND, which may enhance dissolution and bioavailability. Dissolution testing indicated that the printed tablets exhibited improved dissolution rates compared to raw IND powder. The study successfully demonstrated the possibility of SLS-based production for personalized dosing by omitting powder blending steps. The ability to create individualized dosages with minimal excipients and simplified processing represents a step toward further investigation of SLS for clinical settings, including hospital and pharmacy-based drug production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.